<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Merker, Ludwig</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Reductions in HbA1c and Weight in Type 2 Diabetics with the Empagliflozin Add-On Regimen</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-17</style></pages><abstract><style  face="normal" font="default" size="100%">Empagliflozin is a potent and selective inhibitor of sodium glucose cotransporter 2. This article discusses an extension study, the Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes study [EMPA-REG EXTEND MET; NCT01289990], assessed the long-term safety, tolerability, and efficacy of the empagliflozin add-on regimen.</style></abstract><number><style face="normal" font="default" size="100%">20</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>